124 related articles for article (PubMed ID: 27382937)
1. CDX2 as a prognostic marker in gastric cancer.
Masood MA; Loya A; Yusuf MA
Acta Gastroenterol Belg; 2016; 79(2):197-200. PubMed ID: 27382937
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic and immunohistochemical study on early gastric signet-ring cell carcinoma].
Xiong ZF; Xiao H; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):442-6. PubMed ID: 21055171
[TBL] [Abstract][Full Text] [Related]
3. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
[TBL] [Abstract][Full Text] [Related]
4. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis.
Fan Z; Li J; Dong B; Huang X
Clin Cancer Res; 2005 Sep; 11(17):6162-70. PubMed ID: 16144916
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Characteristics and Survival Outcomes of Primary Signet Ring Cell Carcinoma in the Stomach: Retrospective Analysis of Single Center Database.
Liu X; Cai H; Sheng W; Yu L; Long Z; Shi Y; Wang Y
PLoS One; 2015; 10(12):e0144420. PubMed ID: 26642199
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
Roessler K; Mönig SP; Schneider PM; Hanisch FG; Landsberg S; Thiele J; Hölscher AH; Dienes HP; Baldus SE
World J Gastroenterol; 2005 Jun; 11(21):3182-8. PubMed ID: 15929165
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma.
Ge J; Chen Z; Wu S; Yuan W; Hu B; Chen Z
Clin Oncol (R Coll Radiol); 2008 May; 20(4):275-83. PubMed ID: 18353622
[TBL] [Abstract][Full Text] [Related]
8. Gastric cancer patients less than 50 years of age exhibit significant downregulation of E-cadherin and CDX2 compared to older reference populations.
Schildberg CW; Abba M; Merkel S; Agaimy A; Dimmler A; Schlabrakowski A; Croner R; Leupold JH; Hohenberger W; Allgayer H
Adv Med Sci; 2014 Mar; 59(1):142-6. PubMed ID: 24797991
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
[TBL] [Abstract][Full Text] [Related]
10. Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis.
Bai Z; Ye Y; Chen D; Shen D; Xu F; Cui Z; Wang S
APMIS; 2007 Dec; 115(12):1383-90. PubMed ID: 18184409
[TBL] [Abstract][Full Text] [Related]
11. Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer.
Hur H; Kim YB; Ham IH; Lee D
J Surg Oncol; 2015 Nov; 112(6):585-91. PubMed ID: 26381042
[TBL] [Abstract][Full Text] [Related]
12. Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma.
Satake S; Semba S; Matsuda Y; Usami Y; Chiba H; Sawada N; Kasuga M; Yokozaki H
Pathol Int; 2008 Mar; 58(3):156-63. PubMed ID: 18251778
[TBL] [Abstract][Full Text] [Related]
13. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach.
Ko S; Chu KM; Luk JM; Wong BW; Yuen ST; Leung SY; Wong J
J Pathol; 2005 Apr; 205(5):615-22. PubMed ID: 15732140
[TBL] [Abstract][Full Text] [Related]
14. Expression of Cdx2 and the phenotype of advanced gastric cancers: relationship with prognosis.
Mizoshita T; Tsukamoto T; Nakanishi H; Inada K; Ogasawara N; Joh T; Itoh M; Yamamura Y; Tatematsu M
J Cancer Res Clin Oncol; 2003 Dec; 129(12):727-34. PubMed ID: 14557879
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
16. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas.
Almeida R; Silva E; Santos-Silva F; Silberg DG; Wang J; De Bolós C; David L
J Pathol; 2003 Jan; 199(1):36-40. PubMed ID: 12474224
[TBL] [Abstract][Full Text] [Related]
17. Association between environmental factors and CDX2 expression in gastric cancer patients.
Peleteiro B; Lunet N; Wen X; Afonso LP; Mendes N; Barros R; Carneiro F; Almeida R; Barros H
Eur J Cancer Prev; 2012 Sep; 21(5):423-31. PubMed ID: 22157086
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma.
Lin T; Ding YQ; Li JM
Med Oncol; 2012 Jun; 29(2):878-85. PubMed ID: 21336986
[TBL] [Abstract][Full Text] [Related]
19. CDX-2 homeobox gene expression in human gastric carcinoma and precursor lesions.
Kim HS; Lee JS; Freund JN; Min KW; Lee JS; Kim W; Juhng SW; Park CS
J Gastroenterol Hepatol; 2006 Feb; 21(2):438-42. PubMed ID: 16509871
[TBL] [Abstract][Full Text] [Related]
20. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications.
Seno H; Oshima M; Taniguchi MA; Usami K; Ishikawa TO; Chiba T; Taketo MM
Int J Oncol; 2002 Oct; 21(4):769-74. PubMed ID: 12239615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
